Premium
The increasing role of health economic evaluations in drug development
Author(s) -
Annemans Lieven,
Cleemput Irina,
Simoens Steven,
Arickx Francis,
Hulstaert Frank,
Bogaert Marc
Publication year - 2010
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20420
Subject(s) - liberian dollar , equity (law) , health care , currency , business , authorization , actuarial science , value (mathematics) , public economics , population , risk analysis (engineering) , economics , medicine , finance , environmental health , computer science , economic growth , monetary economics , computer security , machine learning , political science , law
The goal of health care policies is to maximize the health of the population within the limits of the available budget and taking into account equity considerations. For innovative drugs, this means that an increasing number are being assessed in terms of their value for money, which is the amount of additional health that can be achieved per additional euro, pound, dollar, or other currency invested. Ideally such assessments and resulting appraisals and decisions should be made in a transparent and efficient way. Transparent means consisting of clear procedures and criteria such as relative effectiveness, cost effectiveness, budget impact, social, and ethical consequences. Transparent also means that stakeholders (physicians, patients, industry, and others) are involved in the assessment and decision‐making process. Efficient means that, on a European level, duplication of efforts is avoided by aligning the processes for market authorization and those for the assessment of value for money. Drug Dev Res 71: 457–462, 2010. © 2010 Wiley‐Liss, Inc.